System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Fabrice Jardin is an expert in Hematology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Fabrice Jardin in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Fabrice Jardin has authored 488 publications, the most recent in 2026, and is an investigator in 55 clinical trials, 21 of them ongoing. SLR score: 2,369 (community average: 125). How the SLR is computed.

LeadR Profile

Fabrice Jardin Centre Henri Becquerel France
2 369 ScienceLeadR Reputation 2369

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Institute for Research and Innovation in Biomedicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 488

Citations

Citations: 11 327 1st author: 33 Last author: 103 Unique author: 10

Main journals

Blood 106
Haematologica 23
J Clin Oncol 22
Hematol Oncol 20
Leuk Lymphoma 18

Best Journals

J Clin Oncol 10
Lancet Oncol 5
Ann Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Potential Benefit of Ruxolitinib in Suspected Ocular and Neurological Transplant-Associated Thrombotic Microangiopathy After Allogeneic Stem Cell Transplantation: A Case Report and Review.
PMID 42819691 — thrombotic microangiopathies, cells, microscopy, electron, scanning transmission, stem cells, transplants, cell transplantation, stem cell transplantation, transplantation		Clin Case Rep20260
SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.
PMID 42802362 — cells, lymphoma, b-cell, lymphoma, aged, b-lymphocytes		Br J Haematol20260
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
PMID 42774885 — cells, lymphoma, b-cell, lymphoma, b-lymphocytes, transplantation		Hemasphere20260
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.
PMID 42715516 — cells, genes, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, classification, therapeutics, mutation, b-lymphocytes, gene expression		J Clin Oncol Top journal20260
Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.
PMID 42699559 — lymphoma, macrophages, lymphoma, large b-cell, diffuse, therapeutics		Blood Neoplasia20260

Clinical Studies 55

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 13 Study Director: 1

By phase:

N/A 19
Phase 3 15
Phase 2 13
Phase 1/Phase 2 5
Phase 2/Phase 3 2
Phase 4 1

By status:

Completed 22
Recruiting 17
Active not recruiting 8
Terminated 3
Unknown 3
Not yet recruiting 2

By type:

Interventional 46
Observational 9

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 7
multicentric5to9 3
multicentricup10 30

Main Topics

Ongoing Clinical Trials

21 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
OASIS II A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma
2024-512634-15-00 — cells, lymphoma, lymphoma, mantle-cell		Phase 1/Phase 2Active not recruiting2022
Apixaban rivaroxaban Versus Aspirin for primary prevention of thrombo embolic complications in JAK2V617F positive myeloproliferative neoplasms
2024-515362-13-00 — thrombocythemia, essential, polycythemia vera, thrombocytosis, rivaroxaban, neoplasms, aspirin, polycythemia, primary prevention, primary myelofibrosis, apixaban		Phase 2/Phase 3Not yet recruiting2024
A clinical study of zilovertamab vedotin in people with large B cell lymphoma (MK 2140 010)
2024-515566-13-00 — cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, b-lymphocytes		Phase 3Recruiting2025
A phase II multicenter open label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subjects with untreated or relapsed refractory high risk mantle cell lymphoma
2023-506706-40-00 — cells, lymphoma, maintenance, lymphoma, mantle-cell		Phase 2/Phase 3Recruiting2025
A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab Cyclophosphamide Doxorubicin and Prednisone (Pola R CHP) Versus Pola R CHP in Previously Untreated Patients with Large B Cell Lymphoma
2023-504028-24-00 — cells, safety, prednisone, lymphoma, b-cell, lymphoma, cyclophosphamide, doxorubicin, rituximab, b-lymphocytes		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS